Enochian BioSciences, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June 27, 2022, both dates inclusive (the “Class Period”), including common stock issued by Enochian in a private placement offering on or about February 16, 2018. If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2022.

If you purchased Enochian BioSciences securities and would like to join the  action, please click “Join This Class Action.”

Class Period:September 24, 2020 through May 31, 2022
If you purchased Enochian BioSciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • Co-founder and inventor, Serhat Gumrukcu, was engaged in a variety of frauds;
  • Gumrukcu was not a licensed doctor anywhere in the world;
  •  Gumrukcu’s purported contributions to Enochian lacked a reasonable basis;
  • Enochian had overstated its commercial prospects;
  • Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and
  • Defendants’ positive statements about Enochian’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis Serhat Gumrukçu, the inventor and co-founder of Enochian BioSciences, was not a licensed doctor and had no verifiable degrees beyond high school;
  • accordingly, the scientific and technological underpinnings of Enochian BioSciences’ product pipeline, purportedly invented by Gumrukçu, were dubious at best;
  • accordingly, the defendants had significantly overstated the commercial prospects for the Company’s product pipeline;
  • Enochian BioSciences’ senior leadership knew Gumrukçuhad a criminal history that included fraud;
  • accordingly, Enochian BioScience’ reliance on Gumrukçu, and its consulting and licensing agreements with G-Tech Bio, LLC and Seraph Research Institute (“SRI”), both of which are controlled by Gumrukçu, subjected the Company to a heightened risk  of reputational and financial harm, as well as threatened the integrity of the Company’s scientific findings; and
  • As a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: Enochian Biosciences, Inc.
Stock Symbol: ENOB
Class Period: January 17, 2018 through June 27, 2022,
Court: United States District Court for the Central District of California

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top